Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 3/20 | 0.58 |
| ▸ | CA1 | P00915 | 3/20 | 0.58 |
| ▸ | CA2 | P00918 | 3/20 | 0.58 |
| ▸ | CA9 | Q16790 | 3/20 | 0.58 |
| ▸ | PYGB | P11216 | 7/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | LGALS1 | P09382 | 2/20 | 0.50 |
| ▸ | LGALS3 | P17931 | 2/20 | 0.50 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.50 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.50 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28378672 | 1.00 | CA12 (0.58) | CA12CA1CA2CA9PYGB | |
| SCHEMBL1224787 | 1.00 | CA12 (0.58) | CA12CA1CA2CA9PYGB | |
| SCHEMBL12894485 | 1.00 | CA12 (0.58) | CA12CA1CA2CA9PYGB | |
| SCHEMBL31510868 | 0.84 | CA12 (0.49) | CA12CA1CA2CA9PYGB | |
| SCHEMBL14067604 | 0.82 | CA1 (0.59) | CA12CA1CA2CA9PYGB | |
| SCHEMBL12603813 | 0.82 | CA12 (0.55) | CA12CA1CA2CA9PYGB | |
| SCHEMBL14707760 | 0.82 | PYGB (0.58) | CA12CA1CA2CA9PYGB | |
| SCHEMBL18722237 | 0.82 | PYGB (0.58) | CA12CA1CA2CA9PYGB | |
| SCHEMBL1647661 | 0.82 | PYGB (0.58) | CA12CA1CA2CA9PYGB | |
| SCHEMBL3228008 | 0.82 | PYGB (0.58) | CA12CA1CA2CA9PYGB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0831847-B1 | METHOD OF SYNTHESIS OF DI-BETA-D-GLUCOPYRANOSYLAMINE COMPOUNDS FOR CONTROLLING INFLAMMATORY REACTIONS | BIODYNAMICS PHARMACEUTICALS IN (US) | 2005-03-09 | — | — | EP | claimed |
| EP-0831847-A2 | USE OF DI-BETA-D-GLUCOPYRANOSYLAMINE COMPOUNDS FOR CONTROLLING INFLAMMATORY REACTIONS, AND METHOD OF SYNTHESIS | Biodynamics Pharmaceuticals, Inc. (US) | 1998-04-01 | — | — | EP | claimed |
| US-5631245-A | Method for medicating the inflammatory controlling system and adverse inflammatory reactions and for making compounds for treating the pathology of adverse inflammatory reactions | BIODYNAMICS PHARMACEUTICALS, INC. (US) | 1997-05-20 | — | — | US | claimed |
| WO-1996039153-A2 | USE OF DI-BETA-D-GLUCOPYRANOSYLAMINE COMPOUNDS FOR CONTROLLING INFLAMMATORY REACTIONS, AND METHOD OF SYNTHESIS | BIODYNAMICS PHARMACEUTICALS, INC. (US) | 1996-12-12 | — | — | WO | claimed |
| CN-115884793-A | Site-specific antibody-drug conjugates with peptide-containing linkers | 梅尔莎纳医疗公司 | 2023-03-31 | — | — | CN | disclosed |
| CN-113365664-A | Cysteine engineered antibody-drug conjugates with peptide-containing linkers | 梅尔莎纳医疗公司 | 2021-09-07 | — | — | CN | disclosed |
| WO-2011083291-A1 | COMBINATIONS COMPRISING AN ANT I -INFLAMMATORY AGENT AND/OR AN ANTIBACTERIAL AGENT AND A GLYCOSYLAMINE AND THEIR USE IN MEDICINE | GALVEZ JULIAN MANUEL (AR) | 2011-07-14 | — | — | WO | disclosed |
| EP-2144920-A1 | NOVEL COMPOUNDS | Diosamine Development Corporation (US) | 2010-01-20 | — | — | EP | disclosed |
| WO-2008152421-A2 | MODIFICATION OF CYTOKINE LEVELS WITH GLUCOSYLAMINE COMPOUNDS | DIOSAMINE DEVELOPMENT CORPORATION (US) | 2008-12-18 | — | — | WO | disclosed |
| WO-2008059003-A1 | NOVEL COMPOUNDS | DIOSAMINE DEVELOPMENT CORPORATION (US) | 2008-05-22 | — | — | WO | disclosed |
| EP-0831847-B1 | METHOD OF SYNTHESIS OF DI-BETA-D-GLUCOPYRANOSYLAMINE COMPOUNDS FOR CONTROLLING INFLAMMATORY REACTIONS | BIODYNAMICS PHARMACEUTICALS IN (US) | 2005-03-09 | — | — | EP | disclosed |
| EP-0831847-B1 | METHOD OF SYNTHESIS OF DI-BETA-D-GLUCOPYRANOSYLAMINE COMPOUNDS FOR CONTROLLING INFLAMMATORY REACTIONS | BIODYNAMICS PHARMACEUTICALS IN (US) | 2005-03-09 | — | — | EP | disclosed |
| EP-0831847-A2 | USE OF DI-BETA-D-GLUCOPYRANOSYLAMINE COMPOUNDS FOR CONTROLLING INFLAMMATORY REACTIONS, AND METHOD OF SYNTHESIS | Biodynamics Pharmaceuticals, Inc. (US) | 1998-04-01 | — | — | EP | disclosed |
| US-5631245-A | Method for medicating the inflammatory controlling system and adverse inflammatory reactions and for making compounds for treating the pathology of adverse inflammatory reactions | BIODYNAMICS PHARMACEUTICALS, INC. (US) | 1997-05-20 | — | — | US | disclosed |
| US-5631245-A | Method for medicating the inflammatory controlling system and adverse inflammatory reactions and for making compounds for treating the pathology of adverse inflammatory reactions | BIODYNAMICS PHARMACEUTICALS, INC. (US) | 1997-05-20 | — | — | US | disclosed |
| WO-1996039153-A3 | USE OF DI-BETA-D-GLUCOPYRANOSYLAMINE COMPOUNDS FOR CONTROLLING INFLAMMATORY REACTIONS, AND METHOD OF SYNTHESIS | BIODYNAMICS PHARMACEUTICALS IN (US) | 1997-03-27 | — | — | WO | disclosed |
| WO-1996039153-A2 | USE OF DI-BETA-D-GLUCOPYRANOSYLAMINE COMPOUNDS FOR CONTROLLING INFLAMMATORY REACTIONS, AND METHOD OF SYNTHESIS | BIODYNAMICS PHARMACEUTICALS, INC. (US) | 1996-12-12 | — | — | WO | disclosed |
| WO-1996039153-A2 | USE OF DI-BETA-D-GLUCOPYRANOSYLAMINE COMPOUNDS FOR CONTROLLING INFLAMMATORY REACTIONS, AND METHOD OF SYNTHESIS | BIODYNAMICS PHARMACEUTICALS, INC. (US) | 1996-12-12 | — | — | WO | disclosed |
| WO-1995018971-A1 | METHODS FOR THE SOLID PHASE SYNTHESIS OF GLYCOCONJUGATES | AFFYMAX TECHNOLOGIES N.V. (NL) | 1995-07-13 | — | — | WO | disclosed |
| EP-0601897-A1 | Method for the preparation of glycosylamines from reducing sugars | ERIDANIA BEGHIN-SAY (FR) | 1994-06-15 | — | — | EP | disclosed |